BackOrchard Therapeutics plc Overview
Orchard Therapeutics plc - ADR

Orchard Therapeutics plc PEG Ratio

Latest PEG ratio for Orchard Therapeutics plc: 106.34 — see history and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

PEG Ratio

106.34

PEG Ratio

106.34

The PEG ratio measures a stock's valuation relative to its earnings growth rate. A PEG ratio below 1.0 may indicate that the stock is undervalued relative to its growth potential.

PEG Ratio (Comparison Companies)

Loading

PEG Ratio History

Loading

PEG Ratio Comparison

Loading

Orchard Therapeutics plc (ORTX) FAQ

Orchard Therapeutics plc (ORTX) currently reports a PEG ratio of 106.34. That is above the Healthcare sector average of 11.77. Use the charts on this page to explore Orchard Therapeutics plc's PEG ratio history and peer comparisons.

Orchard Therapeutics plc's PEG ratio of 106.34 is higher than the Healthcare sector average of 11.77. That is roughly 803.3% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The PEG ratio is a valuation multiple that relates Orchard Therapeutics plc's market price to a fundamental measure such as earnings, sales, or book value. At 106.34, ORTX can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current PEG ratio of 106.34, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 11.77. From there, open related valuation or income-statement pages for Orchard Therapeutics plc, and consider following ORTX for alerts when major investors trade the stock.

Orchard Therapeutics plc is classified in the Healthcare sector. On PEG ratio, it currently shows 106.34 versus a sector average near 11.77. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ORTX with unrelated industries.